Chronic lymphocytic leukemia
暂无分享,去创建一个
[1] D. Mukhopadhyay,et al. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. , 2011, Blood.
[2] Valeria Grieco,et al. Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 , 2003, The Journal of Immunology.
[3] Xiao-Jie Yan,et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. , 2002, Blood.
[4] R. Hendriks,et al. The B Cell Antigen Receptor Controls Integrin Activity through Btk and PLCγ2 , 2003, The Journal of experimental medicine.
[5] G. Packham,et al. B-cell receptor signaling in chronic lymphocytic leukemia. , 2011, Blood.
[6] M. Cragg,et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. , 2010, Seminars in hematology.
[7] K. Haas,et al. The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.
[8] Annelieke Jaspers,et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. , 2007, Blood.
[9] Gabriel Pons,et al. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. , 2006, Experimental hematology.
[10] Ronald Levy,et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.
[11] A. Kohlmann,et al. Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo , 2013, Cancer cell.
[12] H. Urlaub,et al. The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85 , 2011, The EMBO journal.
[13] B. Vanhaesebroeck,et al. Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[14] A. Kretz-Rommel,et al. Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression , 2008, Expert opinion on biological therapy.
[15] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[16] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[17] Juliane C. Dohm,et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.
[18] J. Byrd,et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Drachman,et al. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia , 2010, Leukemia & lymphoma.
[20] Jeffrey A Jones,et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.
[21] E. Vigorito,et al. A Crucial Role for the p110δ Subunit of Phosphatidylinositol 3-Kinase in B Cell Development and Activation , 2002, The Journal of experimental medicine.
[22] R. Rickert,et al. Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases , 2008, The Journal of experimental medicine.
[23] H. Pelicano,et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. , 2012, Blood.
[24] J. Byrd,et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia , 2012, Leukemia & lymphoma.
[25] Z. Estrov,et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. , 2009, Blood.
[26] Jan Delabie,et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.
[27] Kostas Stamatopoulos,et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. , 2012, Blood.
[28] N. Chiorazzi,et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. , 2010, Blood.
[29] W. Wierda,et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. , 2011, Blood.
[30] R. Rosenquist,et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. , 2008, Blood.
[31] K. Stamatopoulos,et al. Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. , 2012, Blood.
[32] Steven L. Allen,et al. Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia , 2004, The Journal of experimental medicine.
[33] Brian J. Smith,et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. , 2005, Blood.
[34] G. Juliusson,et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. , 2003, Blood.
[35] D. Green,et al. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. , 2006, Molecular cell.
[36] R. DePinho,et al. PI3 Kinase Signals BCR-Dependent Mature B Cell Survival , 2009, Cell.
[37] S. Stilgenbauer,et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. , 2009, Blood.
[38] T. Kurosaki,et al. Phospholipase C-γ2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen , 2008, The Journal of Experimental Medicine.
[39] Hirokazu Tamamura,et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. , 2005, Blood.
[40] N. Chiorazzi. Implications of new prognostic markers in chronic lymphocytic leukemia. , 2012, Hematology. American Society of Hematology. Education Program.
[41] W. Khan,et al. Bruton's Tyrosine Kinase Is Required for Activation of Iκb Kinase and Nuclear Factor κb in Response to B Cell Receptor Engagement , 2000, The Journal of experimental medicine.
[42] Jeffrey A Jones,et al. Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals , 2010 .
[43] Lisa S. Chen,et al. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. , 2008, Blood.
[44] A. Rosenwald,et al. IgVH Mutational Status and Clonality Analysis of Richter's Transformation: Diffuse Large B-cell Lymphoma and Hodgkin Lymphoma in Association With B-cell Chronic Lymphocytic Leukemia (B-CLL) Represent 2 Different Pathways of Disease Evolution , 2007, The American journal of surgical pathology.
[45] C. Klein,et al. Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101 , 2011, Molecular Cancer Therapeutics.
[46] A. Osterborg,et al. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. , 2001, The hematology journal : the official journal of the European Haematology Association.
[47] Y. Refaeli,et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. , 2009, Blood.
[48] J. Byrd,et al. A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders , 2012, Clinical Cancer Research.
[49] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[50] R. Dalla‐Favera,et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. , 2013, Blood.
[51] M. Minden,et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling , 2012, Nature.
[52] S. Rhee,et al. Mechanism of B-Cell Receptor-Induced Phosphorylation and Activation of Phospholipase C-γ2 , 2004, Molecular and Cellular Biology.
[53] L. Rassenti,et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.
[54] C. Klein,et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.
[55] C. Croce,et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[56] R. Foà,et al. Molecular pathogenesis of chronic lymphocytic leukemia. , 2012, The Journal of clinical investigation.
[57] J. Leonard,et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] M. Hallek,et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. , 1996, Leukemia & lymphoma.
[59] F. Martín-Saavedra,et al. A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells , 2004, Leukemia.
[60] M. Czuczman,et al. Ofatumumab demonstrates activity against rituximab‐sensitive and ‐resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B‐cell lymphoma , 2012, British journal of haematology.
[61] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[62] W. Khan,et al. Phospholipase C-γ2 Couples Bruton's Tyrosine Kinase to the NF-κB Signaling Pathway in B Lymphocytes* , 2001, The Journal of Biological Chemistry.
[63] V. Quesada,et al. Chronic lymphocytic leukemia with SF3B1 mutation. , 2012, The New England journal of medicine.
[64] A. LaCasce,et al. Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia , 2011, Clinical Cancer Research.
[65] T. Illidge,et al. Radiation Therapy with Tositumomab (B1) Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase–Dependent Cell Death that Overcomes Resistance to Apoptosis , 2008, Clinical Cancer Research.
[66] Ya-jun Guo,et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. , 2009, Blood.
[67] M. Dyer,et al. Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia , 2010 .
[68] B. Cubelos,et al. Essential function for the GTPase TC21 in homeostatic antigen receptor signaling , 2009, Nature Immunology.
[69] L. Pleyer,et al. Molecular and cellular mechanisms of CLL: novel therapeutic approaches , 2009, Nature Reviews Clinical Oncology.
[70] M. Cragg,et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. , 2003, Blood.
[71] D. Oscier,et al. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. , 2003, Blood.
[72] C. Geest,et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.
[73] Göran Roos,et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. , 2004, Blood.
[74] I Royston,et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.
[75] Richard Sherry,et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.
[76] M. Hallek,et al. Prognostic factors in chronic lymphocytic leukemia—what do we need to know? , 2011, Nature Reviews Clinical Oncology.
[77] Lisa L. Smith,et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. , 2004, Blood.
[78] P. Parren,et al. The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 , 2006, The Journal of Immunology.
[79] Jeffrey A Jones,et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] R. Rickert,et al. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. , 2011, Current opinion in immunology.
[81] R. Gascoyne,et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. , 2012, Blood.
[82] C. I. Smith,et al. Redistribution of Bruton's tyrosine kinase by activation of phosphatidylinositol 3‐kinase and Rho‐family GTPases , 2000, European journal of immunology.
[83] M. Jeddi-Tehrani,et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells , 2012, Leukemia.
[84] A. Sepulveda,et al. Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ. , 2010, Gastroenterology.
[85] J. Gribben,et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] F. Ravandi,et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration , 2012, Leukemia.
[87] Tony Pawson,et al. Syk tyrosine kinase required for mouse viability and B-cell development , 1995, Nature.
[88] N. Chiorazzi,et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. , 2012, Blood.
[89] M. Czuczman,et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. , 2009, Blood.
[90] T. Robak,et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] T. Kipps,et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. , 2011, Blood.
[92] S. Akira,et al. Augmented TLR9-induced Btk activation in PIR-B–deficient B-1 cells provokes excessive autoantibody production and autoimmunity , 2009, The Journal of experimental medicine.
[93] B. Coiffier,et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. , 2008, Blood.
[94] Emili Montserrat,et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.
[95] Nikolaos Laoutaris,et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. , 2006, Blood.
[96] Victor L. J. Tybulewicz,et al. The SYK tyrosine kinase: a crucial player in diverse biological functions , 2010, Nature Reviews Immunology.
[97] L. Ginaldi,et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. , 1998, Leukemia research.
[98] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[99] J. Gribben,et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. , 2013, Blood.
[100] B. Cheson,et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. , 2009, Blood.
[101] K. Okkenhaug,et al. The PI3K Isoforms p110α and p110δ Are Essential for Pre–B Cell Receptor Signaling and B Cell Development , 2010, Science Signaling.
[102] D. Rossi,et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. , 2009, Cancer research.
[103] M. Caligiuri,et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. , 2008, Blood.
[104] C. Le Roy,et al. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments , 2012, Haematologica.
[105] M. Keating,et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. , 2011, Blood.
[106] G. Leone,et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells , 2009, Leukemia.
[107] C. Peschel,et al. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL , 2006, Leukemia.
[108] B. Coiffier,et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[109] M. Andreeff,et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] Thomas M. Schmitt,et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. , 2010, Blood.
[111] M. Dyer,et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] W. Fridman,et al. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. , 2010, Blood.
[113] K. Rajewsky,et al. In Vivo Ablation of Surface Immunoglobulin on Mature B Cells by Inducible Gene Targeting Results in Rapid Cell Death , 1997, Cell.
[114] R. Ulrich,et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. , 2011, Blood.